Volume | 0.00 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Quanta Inc (CE) | QNTA | OTCMarkets | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.0001 | 0.0001 |
Trades | Shares Traded | Average Volume | 52 Week Range |
---|---|---|---|
0 | 0.00 | - | 0.0001 - 0.0002 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
- | 0 | US$ 0.0001 | USD |
Quanta Inc (CE) Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
US$ 50.56k | 505.63M | - | - | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Quanta (CE) News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical QNTA Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Year | 0.0002 | 0.0002 | 0.0001 | 0.0001984 | 646,667 | -0.0001 | -50.00% |
3 Years | 0.085 | 0.168 | 0.0001 | 0.0295823 | 2,879,134 | -0.0849 | -99.88% |
5 Years | 2.30 | 19.00 | 0.0001 | 0.0475166 | 1,857,434 | -2.30 | -100.00% |
Quanta (CE) Description
Quanta Inc., an applied science company, focuses on enhancing energy levels in plant matter to increase performance within the human body. Its proprietary technology uses quantum mechanics to increase bioactivity of targeted molecules to enhance the desired effects. The Company specializes in potentiating rare, naturally occurring elements to create impactful and sustainable healing solutions that are as powerful and predictable as pharmaceutical drugs. Through its subsidiary, Medolife Rx, Inc., the company's lead clinical development program includes Escozine, a proprietary formulation consisting of small molecule peptides derived from Rhopalurus princeps scorpions, which is amplified by the Company's polarization technology and is being researched as a treatment of various indications, including COVID-19 and cancer. Medolife Rx has also launched the Immunapen line of immune system enhancers, which meet the needs of people that want to stay healthy, while providing additional benefits such as reduction in anxiety or stress, as well as increased energy and focus. |